Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ , to UK MHRA ® Saint Herblain (France), March 31, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) to potentially expand the use of its chikungunya vaccine, IXCHIQ , currently approved in adults , to adolescents aged 12 to 17 ...